Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
647.70B
Market cap647.70B
Price-Earnings ratio
30.23
Price-Earnings ratio30.23
Dividend yield
2.01%
Dividend yield2.01%
Average volume
6.66M
Average volume6.66M
High today
$262.61
High today$262.61
Low today
$259.65
Low today$259.65
Open price
$261.84
Open price$261.84
Volume
4.85M
Volume4.85M
52 Week high
$274.90
52 Week high$274.90
52 Week low
$172.70
52 Week low$172.70

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $262.25, with a market capitalization of 647.7B. The stock trades at a price-to-earnings (P/E) ratio of 30.23 and offers a dividend yield of 2.01%.

On 2026-08-13, Johnson & Johnson(JNJ) stock moved within a range of $259.65 to $262.61. With shares now at $262.25, the stock is trading +1.0% above its intraday low and -0.1% below the session's peak.

Trading volume for Johnson & Johnson(JNJ) stock has reached 4.85M, versus its average volume of 6.66M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $274.90 and a low of $172.70.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $274.90 and a low of $172.70.

JNJ News

New York Times 7h
Ben Johnson is carrying the Bears, while his bosses keep dropping the ball - The New York Times

...

Ben Johnson is carrying the Bears, while his bosses keep dropping the ball - The New York Times
Simply Wall St 8h
What Johnson & Johnson's Leadership Shift and Cancer Drug Priority Review Mean For Shareholders

Johnson & Johnson recently announced that longtime Innovative Medicine leader Jennifer Taubert has retired after more than 21 years with the company, while Tom...

What Johnson & Johnson's Leadership Shift and Cancer Drug Priority Review Mean For Shareholders
The Motley Fool 8h
Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested Pays Annually.

If you're not aware of them, there's a group of stocks known as Dividend Kings. This select group of companies have all increased their dividends annually for a...

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested Pays Annually.

Analyst ratings

73%

of 26 ratings
Buy
73.1%
Hold
23.1%
Sell
3.8%

More JNJ News

Simply Wall St 15h
Intuitive Surgical Is Facing Fresh Competition In U.S. Surgical Robotics

Intuitive Surgical (NasdaqGS: ISRG) faces new U.S. competition after Johnson & Johnson received FDA authorization for its Ottava robotic surgical system. Ottav...

Intuitive Surgical Is Facing Fresh Competition In U.S. Surgical Robotics
24/7 Wall St. 1d
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield

want a stake in closing that gap. See the offering → (sponsor) Goldman Sachs projects AI demand will exceed compute center capacity for years to come. One Sky...

Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
24/7 Wall St. 1d
The Energy and Pharma Giants Quietly Funding HDV's 3% Yield, and How Safe Each One Is

The Energy and Pharma Giants Quietly Funding HDV’s 3% Yield, and How Safe Each One Is By David Beren Published Aug 12, 12:12PM EDT Quick Read XOM and JNJ earn...

The Energy and Pharma Giants Quietly Funding HDV's 3% Yield, and How Safe Each One Is
Simply Wall St 2d
Johnson & Johnson Advances Seltorexant In Major Depressive Disorder

Johnson & Johnson (NYSE: JNJ) reports progress in its R&D pipeline, including clinical development of seltorexant for major depressive disorder. The company ad...

Johnson & Johnson Advances Seltorexant In Major Depressive Disorder
The Motley Fool 2d
Legend Biotech Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. Tuesday, Aug. 11, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Interim Chief Executive Officer - Alan Bash Chief Financial Officer - C...

Legend Biotech Q2 2026 Earnings Call Transcript
Nasdaq 2d
The U.S. Labor Market Is Weakening. These 2 Dividend Stocks Look Built to Weather a Recession

Key Points The most recent Jobs Report heightened recession fears. Investing in dividend stocks is a great way to navigate recessions. The two stocks below h...

The U.S. Labor Market Is Weakening. These 2 Dividend Stocks Look Built to Weather a Recession
24/7 Wall St. 2d
This 5.3% Monthly Payer Only Buys Stocks That Raised Dividends 10 Straight Years, It's Up 18.5% in 2026

This 5.3% Monthly Payer Only Buys Stocks That Raised Dividends 10 Straight Years, It’s Up 18.5% in 2026 By David Beren Published Aug 11, 4:48PM EDT Quick Read...

This 5.3% Monthly Payer Only Buys Stocks That Raised Dividends 10 Straight Years, It's Up 18.5% in 2026

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.